無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

キメラ抗原受容体 (CAR) T細胞療法の市場機会と課題:標的認識から製品化への発展

Chimeric Antigen Receptor (CAR) T Cell Therapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges

発行 DelveInsight Business Research LLP 商品コード 740512
出版日 ページ情報 英文 626 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.67円で換算しております。
Back to Top
キメラ抗原受容体 (CAR) T細胞療法の市場機会と課題:標的認識から製品化への発展 Chimeric Antigen Receptor (CAR) T Cell Therapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges
出版日: 2018年11月01日 ページ情報: 英文 626 Pages
担当者のコメント
注目のCAR T Cellの市場機会と課題を約600ページの内容でまとめた最新レポートです。2018年11月27日(火)、同社アナリストMridhu Verma氏を招いて、都内で「オンコロジーにおける遺伝子治療・CAR-T細胞療法」をテーマにした特別セミナーを開催します。既に当レポートのご注文企業様、参画を検討中の企業様、及び最新の技術動向、商業化、製品化への課題等関心のある企業様必見のセミナーです https://www.gii.co.jp/seminar/del-seminar2018
概要

当レポートでは、キメラ抗原受容体 (CAR) T細胞療法の技術・製品・企業と開発動向を調査し、CAR-T細胞療法の定義と概要、主要動向・企業および企業間の取り組み、上市済み製品の概要・売上の比較、パイプライン薬の詳細プロファイル、市場参入関連の法規制・手続き、KOLの見解、将来の展望などをまとめています。

第1章 レポート概要

第2章 レポートハイライト

第3章 調査範囲

第4章 主要課題

第5章 エグゼクティブサマリー:概要

第6章 エグゼクティブサマリー

第7章 イントロダクション

第8章 上市済み製品

  • Kymriah:Novartis
  • Yescarta:Kite Pharma (Gilead Sciences)

第9章 CAR-T細胞療法:主要動向・企業展開

  • 提携契約
    • 提携年
    • 投資分析
    • 契約額の動向
    • 将来の発展に向けた企業間提携
  • 買収
    • 買収動向
    • 大手企業による買収提案
    • 製造設備
    • Novartis
    • JW Therapeutics
    • Gilead Sciences Inc.
  • JCAR015:Juno Therapeuticsによる臨床試験の中止
  • 同種CAR-T療法:確実視されるアプローチ
  • CAR-Tライセンシングの機会
  • パイプラインシナリオ
  • 標的:CD19関連製品の開発段階・開発企業

第10章 パイプラインプロファイル

  • Actinium Pharmaceuticals, Inc.
  • AgenTus Therapeutics
  • Allogene Therapeutics
    • ALLO-501
    • ALLO-715
    • ALLO- 819
    • CD70 (NHL)
    • CD70 (RCC)
    • DLL3
  • Anixa Biosciences (ITUS Corporation)
  • Arbele Limited
  • Apceth Biopharma
    • Apceth-301
  • Aurora Biopharma
    • AU101
    • AU105
    • AU55
    • AU180
  • Autolus Limited
  • Avacta Life Sciences Limited
  • Beijing Biohealthcare Biotechnology Co., Ltd
  • Beijing Doing Biomedical Co., Ltd.
  • Beijing Immunochina Medical Science & Technology Co., Ltd.
  • Beijing Sanwater Biological Technology Co., Ltd.
  • Biontech
  • Bellicum Pharmaceuticals Inc.
  • Benitec Biopharma Limited
  • BioInvent International
  • Bluebird bio
  • Creative Biolabs
  • Carina Biotech
  • Carsgen Therapeutics
  • Cell Medica
  • Cellectis
  • Cellular Biomedicine Group Inc.
  • Celyad
  • Chimeric Therapeutics Ltd.
  • CRISPR Therapeutics AG
  • Endocyte
  • Enlivex Therapeutics Ltd
  • Eutilex/Utilities
  • Eureka Therapeutics, Inc
  • Fate Therapeutics
  • Formula Pharmaceuticals
  • GC Cell (Green Cross Cell Corporation)
  • GlaxoSmithKline Plc
  • Guangzhou Bio-gene Technology Co. (Qixi Group)
  • Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
  • Guangzhou YiYang Biological Technology
  • Hunan Zhaotai Yongren Medical Innovation
  • Hebei Senlang Biotechnology Inc., Ltd.
  • Helix BioPharma Corp.
  • Helocyte, Inc.
  • HRAIN Biotechnology
  • Humorigin Inc.
  • Immunicum
  • iCell Gene Therapeutics
  • Immune Therapeutics
  • Innovative Cellular Therapeutics Co., Ltd.
  • Intellia Therapeutics
  • JW Therapeutics
  • Celgene
  • Kite Pharma
  • Les Laboratoires Servier
  • Marino Biotechnology Co., Ltd.
  • Maxcyte
  • Medisix Therapeutics
  • Mimivax LLC
  • MolMed S.p.A.
  • Mustang Bio (Fortress Biotech)
  • Johnson and Johnson
  • Nohla Therapeutics Inc.
  • Novartis Pharmaceuticals
  • Oncternal Therapeutics, Inc
  • Oxford Biomedica
  • PersonGen Biomedicine (Suzhou) Co., Ltd.
  • Pinze Lifetechnology
  • Poseida Therapeutics
  • Pregene (ShenZhen) Biotechnology Company
  • Shanghai GeneChem Co., Ltd.
  • Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
  • Shanghai Longyao Biotechnology
  • Shire plc.
  • Sinobioway Cell Therapy Co., Ltd.
  • Sorrento Therapeutics
  • SymVivo
  • Targazyme
  • タカラバイオ
  • Tessa Therapeutics Pte Ltd.
  • The Beijing Pregene Science and Technology Company, Ltd.
  • TILT Biotherapeutics Ltd
  • Tmunity Therapeutics Inc.
  • Wuhan Sian Medical Technology Co., Ltd.
  • Zhongyuan Xiehe Cell Gene Engineering Co
  • Ziopharm Oncology Inc. and Intrexon、など

第11章 CARを超える技術の展望

第12章 市場参入関連法規制:米国

第13章 市場参入関連法規制:EU

第14章 売上:Kymriah vs Yescarta

第15章 CAR-TへのKOLの見解

第16章 SWOT分析

第17章 FAQ

第18章 調査手法

第19章 コンサルティングサービス

図表

List of Tables

  • Table 1: CARs Generations-Associated Target Antigens and Indications
  • Table 2: CAR-T Cells Therapy - University Collaborations and Deal Year, 2018
  • Table 3: CAR-T Cells Therapy collaboration Deals and Values, 2018
  • Table 4: Companies CAR-T Investment for future developments, 2018
  • Table 5: CAR-T Cells Therapy Acquisitions and Deal Year, 2018
  • Table 6: Companies open for licensing and collaborations, 2018
  • Table 7: umber of Products under Development, 2018
  • Table 8: Number of Products under Development by Companies, 2018
  • Table 9: Number of Products under Development by Indication, 2018
  • Table 10: CAR-T cell Targeted Antigens (%), 2018
  • Table 11: Number of Products under Development by CD19 Targets, 2018
  • Table 12: Number of Products Targeting CD19 Antigen, 2018
  • Table 13: Number of Products Targeting Other Antigens, 2018
  • Table 14:Number of Technology based Products by Company, 2018

List of Figures

  • Figure 1: CAR-T Collaboration Deals, 2018
  • Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2018
  • Figure 3: Number of Products under Development, 2018
  • Figure 4: Number of Products under Development by Companies, 2018
  • Figure 5: Number of Products under Development by Indication, 2018
  • Figure 6: CAR-T cell Targeted Antigens (%), 2018
  • Figure 7: Number of Products under Development by CD19 Targets, 2018
  • Figure 8: Number of Products under Development by CD19 Target (Stage of Development), 2018
  • Figure 9: Number of Products under Development by CD19 Target (Stage of Development), 2018
  • Figure 10: Number of Products under Development by CD19 Target (Stage of Development), 2018
  • Figure 11: Number of Technology based Products by Company, 2018
  • Figure 12: Cost Reduction Strategies for CAR-T Therapy
  • Figure 13: Strategies for CAR T therapy to overcome challenges in treating cancers
  • Figure 14: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis
  • Figure 15: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide
  • Figure 16: CAR T cells with “ON switch”- small molecules
  • Figure 17: CAR T cells with “ON/OFF switch”
目次

Introduction

“Chimeric Antigen Receptor (CAR) T-Cell Therapy- Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges” offers a descriptive overview of the CAR-T Cell Therapy Market industry, which includes: CAR-T therapy global competitive landscape, CAR-T combination therapies, current prominent research areas, key players, geography-wise regulatory requirements (USA and Europe), technological breakthroughs, market trends and dynamics, strategies of key players and cost reduction analysis etc. which would help companies to strengthen their position in the CAR-T Therapy market. The report also offers a comprehensive evaluation of the CAR-T market. The report features a complete qualitative and quantitative assessment by analyzing data gathered from secondary and primary market research (industry analysts and market participants across key points in the industry's value chain).

The report provides an in-depth analysis of key market trends and governing factors along with market attractiveness as per segments. The report also provides the qualitative impact of various market factors on various CAR-T market segments and geographies. The comprehensive insights provided in this report will help the companies in identifying better opportunities. The Report covers the 102 companies with 286 CAR-T therapies, which are active in this field including 35+ leading companies with 71 products targeting more than 28 different antigens and more than 31 different technologies.

The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens, Investments and fundings etc. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by cost-analysis and SWOT Analysis. The report also covers the KOL views on CAR-T Therapy. Additionally, the report covers the comparative analysis of the sales of two approved drugs (Kymriah and Yescarta). Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells. The strategists can gain a detailed insight and devise appropriate strategies to target specific market.

Table of Contents

1. Report Introduction

2. Report Highlights

3. Scope

4. Key Questions Answered

5. Executive Summary Snapshot

6. Executive Summary

7. Introduction

  • 7.1. Cancer Immunotherapy
  • 7.2. Adoptive T cell transfer (ACT)
  • 7.3. Chimeric Antigen Receptor (CAR) T-cells
  • 7.4. CARS Generations
  • 7.5. CARs Generations: Snapshot
  • 7.6. CAR-T Cell Therapy Design
  • 7.7. Genetic Engineering of T-Cells
  • 7.8. Necessity of 2nd Generation and 3rd generation CAR Signalling
  • 7.9. Co-stimulatory domains
    • 4-1BB (CD137): Just a glance
  • 7.10. Advantages of CAR-T cells
  • 7.11. Adverse Events with CAR T-cell Therapy
    • Acute Infusion Reactions
    • On-target Toxicities
    • Organ-specific toxicities:
  • 7.12. Limitations of Existing Technologies for CAR T-Cells

8. Marketed Products

  • 8.1. Kymriah: Novartis
  • 8.2. Yescarta: Kite Pharma (Gilead Sciences)

9. CAR-T Cell Therapy-Analysis

  • 9.1. CAR-T Collaboration Deals
    • CAR-T Cells Therapy Collaborations and Deal Year
    • CAR-T Investment Analysis
    • Collaborations & Deal Value Trends
    • Companies collaborations for future developments
  • 9.2. CAR-T Acquisitions Deals
    • CAR-T Cells Therapy Acquisitions Trends
    • CAR-T Cells Therapy Acquisitions Offerings by Big Giants
    • Manufacturing Facilities for the Development of CAR-T cells
    • Novartis
    • JW Therapeutics
    • Gilead Sciences Inc.
  • 9.3. JCAR015: Major Set Back for Juno Therapeutics
  • 9.4. Allogeneic CAR-T therapy: a promising approach in CAR-T space
  • 9.5. CAR-T Licensing Opportunities
  • 9.6. Pipeline Scenario
    • Pipeline Products under Development - An Overview
    • Pipeline Products under Development by Company
    • CAR T-cells Therapeutic Areas & Companies
    • CAR-T cells Targeted Antigens
  • 9.8. Target: CD19 Related Drug Products, Phase & Company
    • CAR T-cell Technologies & Companies Involved
    • CAR-T Safety Switches & Company Involved
    • Companies with Upcoming CAR-T Therapeutics

10. Pipeline Profiles

  • 10.1. Actinium Pharmaceuticals, Inc.
  • 10.2. AgenTus Therapeutics
  • 10.3. Allogene Therapeutics
    • ALLO-501 - Allogene Therapeutics Inc.
    • ALLO-715: Allogene Therapeutics
    • ALLO- 819: Allogene Therapeutics
    • CD70 (NHL): Allogene Therapeutics
    • CD70 (RCC): Allogene Therapeutics
    • DLL3: Allogene Therapeutics
  • 10.4. Anixa Biosciences (formerly ITUS Corporation)
    • Solid Tumor Therapy Program: Anixa Biosciences
  • 10.5. Arbele Limited
    • ARB-301: Arbele Limited
    • Disruptive CAR-T/TCR-T : Arbele Limited
    • Disruptive CAR-T/TCR-T : Arbele Limited
  • 10.6. Apceth Biopharma
    • Apceth-301:Apceth Biopharma
  • 10.7. Aurora Biopharma
    • AU101: Aurora Biopharma
    • AU105: Aurora Biopharma
    • AU55: Aurora Biopharma
    • AU180: Aurora Biopharma
  • 10.8. Autolus Limited
    • AUTO3: Autolus Limited
    • AUTO2: Autolus Limited
    • AUTO1: Autolus Therapeutics Ltd.
  • 10.9. Avacta Life Sciences Limited
    • AVA-008: Avacta Life Sciences Limited
  • 10.10. Beijing Biohealthcare Biotechnology Co., Ltd
    • Anti-CD20 chimeric antigen receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,
    • CD19-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
    • CD33-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
    • CD138-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
    • HER1-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
    • CD30-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
    • CD133-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
    • EGFR-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
    • HER2-targeted Chimeric Antigen Receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd
  • 10.11. Beijing Doing Biomedical Co., Ltd.
    • Anti-CD19-CAR: Beijing Doing Biomedical
    • Anti-CD19 anti-CD20 Bispecific CAR-T: Beijing Doing Biomedical
  • 10.12. Beijing Immunochina Medical Science & Technology Co., Ltd.
    • IM19 CAR-T: Beijing Immunochina Medical Science & Technology Co., Ltd.
  • 10.13. Beijing Sanwater Biological Technology Co., Ltd.
    • CART-19: Beijing Sanwater Biological Technology Co., Ltd.
  • 10.14. Biontech
    • FPI2019: Biontech
  • 10.15. Bellicum Pharmaceuticals Inc.
    • BPX-601: Bellicum Pharmaceuticals Inc.
    • Anti-GD2-CAR engineered T cells: Bellicum Pharmaceuticals Inc.
    • CD19 CAR-T Cell therapy: Bellicum Pharmaceuticals Inc.
    • CD123 CARs: Bellicum Pharmaceuticals Inc
  • 10.16. Benitec Biopharma Limited
    • ddRNAi CAR-T Program: Benitec Biopharma Limited
  • 10.17. BioInvent International
    • CAR-T Programme: BioInvent International
  • 10.18. Bluebird bio
    • BB2121: Bluebird Bio
    • bb21217: bluebird bioInc.
  • 10.19. Creative Biolabs
  • 10.20. Carina Biotech
    • CNA1003: Carina Biotech
  • 10.21. Carsgen Therapeutics
    • CAR-GPC3: Carsgen Therapeutics
    • CAR-EGFR: Carsgen Therapeutics
    • CAR-CD19: Carsgen Therapeutics
    • CAR-CLD18 T: Carsgen Therapeutics
  • 10.22. Cell Medica
    • CMD-501: Cell Medica
    • CMD-502: Cell Medica
    • CMD-503: Cell Medica
    • CMD-504: Cell Medica
  • 10.23. Cellectis
    • UCART123: Cellectis
    • UCART38: Cellectis
    • UCARTCS1: Cellectis
    • UCART22: Cellectis
  • 10.24. Cellular Biomedicine Group Inc.
    • C-CAR011: Cellular Biomedicine Group Inc.
    • Anti-CD20 CAR: Cellular Biomedicine Group Inc.
    • CAR-T CD30: Cellular Biomedicine Group Inc.
    • CART-EGFR: Cellular Biomedicine Group Inc.
    • BiCAR: Cellular Biomedicine Group Inc.
    • CD20-CD19 Bispecific CAR: Cellular Biomedicine Group Inc
    • PD-1 KO CAR: Cellular Biomedicine Group Inc.
    • Anti-CD22 CAR: Cellular Biomedicine Group Inc.
  • 10.25. Celyad
    • CYAD-01: Celyad
    • CYAD-03 or CAR-T B7H6: Celyad
    • CAR-T NKR-3: Celyad
  • 10.26. Chimeric Therapeutics Ltd.
    • CLEC14a CAR-transduced T-cells:Chimeric Therapeutics Ltd.
  • 10.27. CRISPR Therapeutics AG
    • CTX101: CRISPR Therapeutics AG
  • 10.28. Endocyte
    • Adaptor-Controlled Chimeric Antigen Receptor (CAR)- T cell therapy: Endocyte
  • 10.29. Enlivex Therapeutics Ltd
    • Allocetra for Solid Tumor "immune checkpoint" + CAR T (CAR-T Combination): Enlivex Therapeutics Ltd. (Hadasit Bio-Holdings Ltd. Company)
  • 10.30. Eutilex/Utilities
    • Solid cancer specialized CAR-T: Eutilex/Utilities
    • MVR CAR-T: Eutilex/Utilities
  • 10.31. Eureka Therapeutics, Inc
    • ET140202: Eureka Therapeutics, Inc
    • ET190L1 ARTEMIS: Eureka Therapeutics, Inc
    • ET1501: Eureka Therapeutics, Inc
    • ET1502: Eureka Therapeutics, Inc
    • ET1504: Eureka Therapeutics, Inc
  • 10.32. Fate Therapeutics
    • FT-819 Engineered CAR iT Cell: Fate Therapeutics
  • 10.33. Formula Pharmaceuticals
    • CIK-CAR.CD19: Formula Pharmaceuticals
    • CIK-CAR.PSMA: Formula Pharmaceuticals
    • Solid and hematologic tumor targets CAR-T Program: Formula Pharmaceuticals
  • 10.34. GC Cell (Formerly known as Green Cross Cell Corporation)
  • 10.35. GlaxoSmithKline Plc
    • CAR-T Cell therapy: GlaxoSmithKline plc
  • 10.36. Guangzhou Bio-gene Technology Co. (a subsidiary of Qixi Group)
    • BG-T19: Guangzhou Bio-gene Technology Co.
  • 10.37. Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
    • GPC3 targeting CAR-T cells: Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
    • HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T cell therapy : Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
  • 10.38. Guangzhou YiYang Biological Technology
    • CAR-T Cell Immunotherapy: Guangzhou YiYang Biological Technology
  • 10.39. Hunan Zhaotai Yongren Medical Innovation
    • Zeushield Cytotoxic T Lymphocytes: Hunan Zhaotai Yongren Medical Innovation
  • 10.40. Hebei Senlang Biotechnology Inc., Ltd.
    • Autologous CD19-targeting CAR T cells (Senl-001): Hebei Senlang Biotechnology Inc., Ltd.
    • L1CAM CAR-T: Hebei Senlang Biotechnology Inc., Ltd.
    • Individualized preciseCAR-T treatment: Hebei Senlang Biotechnology Inc., Ltd.
    • HSPC-NK-CAR: Hebei Senlang Biotechnology Inc., Ltd
  • 10.41. Helix BioPharma Corp.
    • CAR-T Cell Therapy targeting CEACAM6: Helix BioPharma Corp.
    • CAR-T Cell Therapy targeting VEGFR2: Helix BioPharma Corp.
    • Bispecific CAR-T Cell therapy for Hematological cancers: Helix BioPharma Corp.
  • 10.42. Helocyte, Inc.
    • Triplex + CAR-Ts: Helocyte, Inc.
  • 10.43. HRAIN Biotechnology
    • Human CD19 Targeted T Cells Injection Therapy: Hrain Biotechnology Co.,Ltd.
    • Anti-CD19/BCMA Bispecific CAR-T Cell Therapy: Hrain Biotechnology
    • BCMA Chimeric Antigen Receptor Therapy : Hrain Biotechnology
  • 10.44. Humorigin Inc.
    • HORC020: Humorigin Inc.
    • HORC030: Humorigin Inc.
    • HO-C019 (CD19) : Humorigin Inc.
    • HO-C010 (2ND Generation) (CD30) : Humorigin Inc.
    • HO-C021 (New generation) : Humorigin Inc.
  • 10.45. Immunicum
    • IMM-3: Immunicum
  • 10.46. iCell Gene Therapeutics
    • CLL1b-CD33b compound CAR: iCell Gene Therapeutics
    • ICG122: iCell Gene Therapeutics
    • CD3CAR: iCell Gene Therapeutics
    • ICG124: iCell Gene Therapeutics
    • CAR T cell therapy for B cell malignancies: iCell Gene Therapeutics
    • CAR T cell therapy for Multiple myeloma: iCell Gene Therapeutics
    • Allogenic CARs Program: iCell Gene Therapeutics
    • Universal CARs Program: iCell Gene Therapeutics
    • Antigen Escape Resistant CARs Program: iCell Gene Therapeutics
    • Immune Suppression Resistant CARs Program: iCell Gene Therapeutics
    • CARs with Increased Signaling Program: iCell Gene Therapeutics
    • Non Hematological CARs Program: iCell Gene Therapeutics
  • 10.47. Immune Therapeutics
    • Chinese Chimeric Super Antigen Receptor T cell cocktail: Immune Therapeutics
  • 10.48. Innovative Cellular Therapeutics Co., Ltd.
    • CD19CART: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR028: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR018: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR039: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR029: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR017: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR032: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR038: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR016: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR003: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR014: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR043: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR023: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR046: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR049: Innovative Cellular Therapeutics Co., Ltd.
    • ICTCAR050: Innovative Cellular Therapeutics Co., Ltd.
  • 10.49. Intellia Therapeutics
    • CRISPR-Cas9-based therapies using chimeric antigen receptor T cells Programme: Intellia Therapeutics
  • 10.50. JW Therapeutics
    • JWCAR029: JW Therapeutics
  • 10.51. Celgene
    • JCAR014 Combination: Celgene
    • JCAR017: Celgene
    • JCAR 023: Celgene
    • JCAR 018: Celgene
    • JCAR020: Celgene
    • JCAR024: Celgene
    • BCMA targeting CAR: Celgene
    • CD19 Armored CAR: Celgene
    • CD19 Fully Human scFv CAR: Celgene
  • 10.52. Kite Pharma
    • Human Anti-CD19: Kite Pharmaceuticals Inc.
    • KITE-585: Kite Pharmaceuticals Inc.
    • KITE-796: Kite Pharmaceuticals Inc.
  • 10.53. Les Laboratoires Servier
    • UCART19: Allogene Therapeutics/ Les Laboratoires Servier
  • 10.54. Marino Biotechnology Co., Ltd.
    • Anti-mesothelin CAR T: Marino Biotechnology Co., Ltd.
    • Anti-EGFRvIII CAR T:Marino Biotechnology Co., Ltd.
    • CD19 CAR T:Marino Biotechnology Co., Ltd.
    • iPD1 CD19 eCAR T cells: Marino Biotechnology
  • 10.55. Maxcyte
    • MCY-M11:Maxcyte
    • MCY-C55: Maxcyte
  • 10.56. Medisix Therapeutics
    • Chimeric Antigen Receptor (CAR) T-cell Immunotherapies: Medisix Therapeutics
  • 10.57. Mimivax LLC
    • MV97183:Mimivax LLC
  • 10.58. MolMed S.p.A.
    • CAR-CD44v6:MolMed S.p.A.
  • 10.59. Mustang Bio (Subsidiary of Fortress Biotech)
    • MB-101:Mustang Bio
    • MB-102: Mustang Bio
    • MB-103:Mustang Bio
    • MB-104:Mustang Bio
    • MB-105:Mustang Bio
    • MB-106 CD20 CAR: Mustang Bio
  • 10.60. Johnson and Johnson
    • LCAR-B38M: Nanjing Legend Biotech Co./ Janssen Biotech
  • 10.61. Nohla Therapeutics Inc.
    • Progenitor Cell CARs/ NLA 102:Nohla Therapeutics Inc.
  • 10.62. Novartis Pharmaceuticals
    • CTL119: Novartis Pharmaceuticals
    • CART-meso: Novartis Pharmaceuticals
    • CAR-T-EGFRvIII: Novartis Pharmaceuticals
    • CART-BCMA: Novartis Pharmaceuticals
    • cMet RNA CAR T Therapy: Novartis Pharmaceuticals
    • CART22 Therapy: Novartis Pharmaceuticals
    • Undisclosed CAR-T: Novartis Pharmaceuticals
  • 10.63. Oncternal Therapeutics, Inc
    • Chimeric Antigen Receptor T cell therapy: Oncternal Therapeutics, Inc.
  • 10.64. Oxford Biomedica
    • OXB-302:Oxford Biomedica
  • 10.65. PersonGen Biomedicine (Suzhou) Co., Ltd.
    • Anti-MUC1 CAR-pNK cells: PersonGen Biomedicine (Suzhou) Co., Ltd.
    • PCAR-019: PersonGen Biomedicine (Suzhou) Co., Ltd
    • PCAR-119: PersonGen Biomedicine (Suzhou) Co., Ltd
  • 10.66. Pinze Lifetechnology
    • PZ01: Pinze Lifetechnology
  • 10.67. Poseida Therapeutics
    • P-BCMA-101: Poseida Therapeutics
    • P-PSMA-101: Poseida Therapeutics
    • PMUC1C-101: Poseida Therapeutics
    • P-BCMA-ALLO1: Poseida Therapeutics
  • 10.68. Pregene (ShenZhen) Biotechnology Company
    • BCMA CAR-T Cells: Pregene (ShenZhen) Biotechnology Company
    • CD19 CAR-T Cells: Pregene (ShenZhen) Biotechnology Company
    • EGFR IL12 CART: Pregene (ShenZhen) Biotechnology Company
  • 10.69. Shanghai GeneChem Co., Ltd.
    • CD19-CART: Shanghai GeneChem Co., Ltd.
    • CD22-CART Shanghai GeneChem Co., Ltd.
    • CD123-targeted monoclonal antibody: Shanghai GeneChem Co., Ltd.
    • MG7-CART: Shanghai GeneChem Co., Ltd.
    • CEA- CART: Shanghai GeneChem Co., Ltd.
    • TAI-meso-CART: Shanghai GeneChem Co., Ltd
    • GPC3 - CART: Shanghai GeneChem Co., Ltd.
    • BCK - CART:Shanghai GeneChem Co., Ltd.
    • EGFRv III - CART:Shanghai GeneChem Co., Ltd.
    • CD30- CART:Shanghai GeneChem Co., Ltd.
    • CD33- CART:Shanghai GeneChem Co., Ltd.
    • GD2- CART:Shanghai GeneChem Co., Ltd.
    • Her2- CART:Shanghai GeneChem Co., Ltd.
  • 10.70. Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
    • CD19/CD20/CD22/CD30 CAR-T cell therapy: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
    • CD19 CAR-T cell therapy: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
    • Humanized CD19 CAR-T cells: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
    • CART-19/22:Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
    • Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy :Shanghai Unicar-Therapy medicine Technology Co.,Ltd.
    • Chimeric antigen receptor T cell : Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
  • 10.71. Shanghai Longyao Biotechnology
    • Anti-CD19 and Anti-CD20 CAR-T Cells: Shanghai Longyao Biotechnology
    • Anti-CD20 CAR-T Cells: Shanghai Longyao Biotechnology
  • 10.72. Shire plc.
    • Allogeneic chimeric antigen receptor (CAR) T cell therapies:Shire plc
  • 10.73. Sinobioway Cell Therapy Co., Ltd.
    • GD2-targeted CAR-T cells: Sinobioway Cell Therapy Co., Ltd.
    • CD19-targeted CAR-T cells: Sinobioway Cell Therapy Co., Ltd.
    • EPCAM-targeted CAR-T cells: Sinobioway Cell Therapy Co., Ltd.
  • 10.74. Sorrento Therapeutics
    • CEA CAR-T: Sorrento Therapeutics
    • PSMA CAR-T -cell immunotherapy: Sorrento Therapeutics
    • CD38 CAR-T: Sorrento Therapeutics
    • IL13R CAR-T:Sorrento Therapeutics
    • GD3 CAR-T:Sorrento Therapeutics
    • c-KIT CAR-T:Sorrento Therapeutics
    • CAR.TNK-PDL1:Sorrento Therapeutics
    • CAR.TNK-ROR1:Sorrento Therapeutics
    • HER2.TNK:Sorrento Therapeutics
    • CD123.TNK:Sorrento Therapeutics
    • EGFRViii.TNK:Sorrento Therapeutics
    • EphA3.TNK:Sorrento Therapeutics
    • L1CAM.TNK:Sorrento Therapeutics
    • CSPG4.TNK:Sorrento Therapeutics
    • BCMA.TNK:Sorrento Therapeutics
    • CS1.TNK:Sorrento Therapeutics
    • CD19.TNK:Sorrento Therapeutics
    • CD22.TNK:Sorrento Therapeutics
    • PSCA.TNK:Sorrento Therapeutics
  • 10.75. SymVivo
    • bacTRL+ CAR T-cell therapy:SymVivo
  • 10.76. Targazyme
    • TZ-102: Targazyme
  • 10.77. Takara Bio
    • TBI-1501:Takara Bio
  • 10.78. Tessa Therapeutics Pte Ltd.
    • TT14:Tessa Therapeutics Pte Ltd.
    • Virus-Specific T (VST) Cells & Chimeric Antigen Receptors (CAR) T cell therapy combination program:Tessa Therapeutics Pte Ltd.
    • HER2-CAR VST + CAdVEC : Tessa Therapeutics Pte Ltd.
  • 10.79. The Beijing Pregene Science and Technology Company, Ltd.
    • CART-19 cells:The Beijing Pregene Science and Technology Company, Ltd.
    • EGFR CART:The Beijing Pregene Science and Technology Company, Ltd.
  • 10.80. TILT Biotherapeutics Ltd
    • TILT-123: TILT Biotherapeutics Ltd
  • 10.81. Tmunity Therapeutics Inc.
    • CAR-T Program:Tmunity Therapeutics Inc.
    • TMUN ONC 003: Tmunity Therapeutics Inc.
    • TMUN ONC 004: Tmunity Therapeutics Inc.
    • TMUN ONC 001: Tmunity Therapeutics Inc.
  • 10.82. Wuhan Sian Medical Technology Co., Ltd.
    • CD19 Chimeric Antigen Receptor (CAR)-modified T Cell Therapy: Wuhan Sian Medical Technology Co., Ltd.
  • 10.83.
  • 10.84. Zhongyuan Xiehe Cell Gene Engineering Co
    • CD19 CAR T cells: Zhongyuan Xiehe Cell Gene Engineering Co.
    • CD33 CAR T cells: Zhongyuan Xiehe Cell Gene Engineering Co.
  • 10.85. Ziopharm Oncology Inc. and Intrexon
    • CD33 CAR-T Cell therapy: Ziopharm Oncology Inc. and Intrexon
    • CD19 3rdGen with Cytokine: Ziopharm Oncology Inc. and Intrexon
    • Myeloid malignancies CAR-T Programme: Ziopharm Oncology Inc. and Intrexon
    • Merck Target 1: Ziopharm Oncology Inc. and Intrexon
    • Merck Target 2: Ziopharm Oncology Inc. and Intrexon
    • CAR (POC): Ziopharm Oncology Inc. and Intrexon

11. Upcoming Technologies Better than CARs

12. US regulatory route to market:

  • 12.1. Various Types of expedited approvals in US

13. EU regulatory route to market

  • 13.1. Various Types of expedited approvals in EU:
  • 13.2. Strategic Analysis of Reimbursement Policies for CAR-T Cell Therapy
  • 13.3. Summary of Coverage Policies
    • Centers for Medicare & Medicaid Services (CMS): Medicare and Medicaid
    • CMS Medicare reimbursement for CAR T-cell therapy, as of January 19, 2018:
  • 13.4. England's NHS to offer Gilead's Yescarta through Cancer Drugs Fund
  • 13.5. Strategies to reduce the cost of CAR-T

14. Sales: Kymriah versus Yescarta

15. KOL Views on CAR-T

  • What is the KOL impression of CAR T-cell therapy based on prior research and new findings presented during the 2018 ASCO Annual Meeting?
  • What new research on CAR T-cell therapy presented at ASCO excited KOL the most?
  • What major questions about CAR T-cell therapy remain to be addressed?
  • What caution would the KOL give to their peers about administering CAR T-cell therapy?
  • How is the cost of CAR T-cell therapy compared with other treatment approaches, and how that influence treatment decision-making?

16. SWOT Analysis

17. Frequently Asked Questions

  • Why should I purchase DelveInsight's report? How is it different from other market vendors?
  • I am based out in Japan. How will your report help me in identifying overall CAR-T cells opportunities in Japan?
  • I want to commercialize my CAR-T cell Therapy across Globe. How does your report help in identifying key opportunities across the globe?
  • Does your report provide in-depth analysis of all possible Pros and Cons in the development T cells Therapy?
  • How does your report help solving the current challenges being faced by the CAR-manufacturers in the development and commercialization of this Therapy?
  • How does your report tackle the challenge of high pricing and cost associated with the therapy?

18. Report Methodology

19. Consulting Services

Back to Top